Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: A gene pathway analysis

Pharmacogenomics Journal

Volumn 11, Issue 6, 2011, Pages 412-418

  Bonelli, P ^a   Tuccillo, F M ^a   Calemma, R ^a   Pezzetti, F ^b   Borrelli, A ^a   Martinelli, R ^c,d   De Rosa, A ^a   Esposito, D ^a   Palaia, R ^a   Castello, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

cell cycle control; gene expression profile; ibuprofen; MKN 45 cell line; pathway analysis

Indexed keywords

CYTOCHROME P450; IBUPROFEN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; THYMIDINE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPLICATION; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TIME SERIES ANALYSIS; TREATMENT RESPONSE; UPREGULATION;

ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IBUPROFEN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REACTIVE OXYGEN SPECIES; STOMACH NEOPLASMS;

EID: 81755163639     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.55     Document Type: Article

References (32)

1. Hinz B, Brune K. Antipyretic analgesics: nonsteroidal antiinflammatory drugs, selective COX-2 inhibitors, paracetamol and pyrazolinones. Handb Exp Pharmacol 2007; 177: 65-93.
2. Kokoska ER, Smith G, Wolff AB, Deshpande Y, Miller TA. Nonsteroidal antiinflammatory drugs attenuate epidermal growth factor-induced proliferation independent of prostaglandin synthesis inhibition. J Surg Res 1999; 84: 186-192. (Pubitemid 29389996)
3. Thun AJ. NSAID use and decreased risk of gastrointestinal cancers. Gasteroenterol Clin North Am 1996; 25: 333-348.
4. Giardiello FM. NSAID-induced polyp regression in familial adenomatous polyposis patients. Gasteroenterol Clin North Am 1996; 25: 349-362.
5. Barnes CJ, Lee M. Non-steroidal anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Gastroenterology 1998; 114: 873-877.
6. Fratelli M, Minto M, Crespi A, Erba E, Vandenabeele P, Del Soldato P et al. Inhibition of nuclear factor-kappaB by a nitro-derivative of flurbiprofen: a possible mechanism for antiinflammatory and antiproliferative effect. Antioxis redox Signal 2003; 5: 229-235. (Pubitemid 36457598)
7. Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 2003; 37: 1-24. (Pubitemid 36767977)
8. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of antiinflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Br Med J 2000; 320: 1642-1646. (Pubitemid 30364636)
9. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Nonsteroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003; 95: 1784-1791. (Pubitemid 38008901)
10. Giovannucci E, Egan KM, Hunter DJ. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-614.
11. de Groot DJ, de Vries EG, Groen HJ, de Jong S. Non-steroidal antiinflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 2007; 61: 52-69. (Pubitemid 44880148)
12. Palayoor ST, Tofilon PJ, Coleman CN. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1a and HIF-2a in prostate cancer cells. Clin Cancer Res 2003; 9: 3150-3157. (Pubitemid 37006311)
13. Janssen A, Majer TJ, Schiffmann S, Coste O, Seegel M, Geisslinger G et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S-or R-ibuprofen treatment. Eur J Pharmacol 2006; 540: 24-33. (Pubitemid 43884823)
14. John-Aryankalayil M, Palayoor ST, Cerna D, Falduto MT, Scott R, Coleman CN. NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther 2009; 8: 261-273.
15. Raju U, Nakata E, Yang P, Newman RA, Ang KK, Milas L. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 2002; 54: 886-894.
16. Minter HA, Eveson JW, Huntley S, Elder DJ, Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res 2003; 9: 1885-1897. (Pubitemid 36554617)
17. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IkB kinase a and NF-kB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18: 7389-7394. (Pubitemid 30032121)
18. Andrews J, Djakiew D, Krygier S, Andrews P. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol 2002; 50: 277-284.
19. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-2072. (Pubitemid 32927924)
20. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311. (Pubitemid 30151999)
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2DDCt method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
22. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal antiinflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004; 23: 9247-9258. (Pubitemid 40069695)
23. Thurnher D, Bakroeva M, Formanek M, Knerer B, Kornfehl J. Nonsteroidal anti-inflammatory drugs inhibit telomerase activity in head and neck squamous carcinoma cell lines. Head Neck 2001; 23: 1049-1055. (Pubitemid 33107935)
24. Sawaoka H, Kawano S, Tsujii M, Gunawan ES, Takei Y, Nagano K et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998; 274: 1061-1067.
25. de Groot DJ, de Vries EG, Groen HJ, de Jong S. Non-steroidal antiinflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 2007; 61: 52-69. (Pubitemid 44880148)
26. Redpath M, Marques CM, Dibden C, Waddon A, Lalla R, Macneil S. Ibuprofen and hydrogel-released ibuprofen in the reduction of inflammation-induced migration in melanoma cells. Br J Dermatol 2009; 161: 25-33.
27. Quann EJ, Khwaja F, Djakiev D. The p38 MAPK pathway mediates aryl propionic acid induced messenger RNA stability of p75 NTR in prostate cancer cells. Cancer Res 2007; 67: 11402-11410. (Pubitemid 350248568)
28. Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000; 12: 676-684.
29. Viallard JF, Lacombe F, Belloc F, Pellgrin JL, Reiffers J. Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology. Cancer Radiother 2001; 5: 109-129. (Pubitemid 32374713)
30. Waldman T, Kinzler KW, Vogelstein B. P21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55: 5187-5190.
31. Cam H, Dynlacht BD. Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell 2003; 3: 311-316. (Pubitemid 38340300)
32. Chandra D, Liu JW, Tang DG. Early mitochondrial activation and cytochrome c up-regulation during apoptosis. J Biol Chem 2002; 277: 50842-50854. (Pubitemid 36042250)